The english version of the website of the School of Medicine is under development

Δημοσίευση

Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires.

TitleMonitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires.
Publication TypeJournal Article
Year of Publication2018
AuthorsTremmas, I., Petsatodis G., Potoupnis M., Laskou S., Giannakidis D., Mantalovas S., Koulouris C., Katsaounis A., Pavlidis E., Amaniti A., Huang H., Bai C., Shi D., Dardas A., Zarogoulidis P., Sardeli C., Konstantinou F., Katsikogiannis N., Zarogoulidis K., Karapantzos I., Karapantzou C., Shen X., Kesisoglou I., & Sapalidis K.
JournalJ Cancer
Volume9
Issue10
Pagination1731-1736
Date Published2018
ISSN1837-9664
Abstract

Due to the severity of the primary disease in patients with lung cancer, quality of life (QoL) is often overlooked. Factors that form QoL should be taken in consideration when planning the appropriate treatment and determining therapy targets, because of the increasing frequency of bone metastasis leading to high levels of pain. Purpose of this study is to assess quality of life in patients with lung cancer, before and after treatment combined with zoledronic acid. QoL was assessed in 80 patients (49 males-31 females), of which 45 developed bone metastasis. Prior and post treatment (with co administration of zoledronic acid) seven reliable scales: Pittsburgh Sleep Quality index (PSQI), Epworth Sleeping Scale (ess), Dyspnea Scale (ds), Fatigue Severity Scale (FSS), Brief Pain Inventory (BPI), Fact-G scale for sleep quality and EQ-5D for general health condition. Statistically positive correlations were verified between PSQI-DS, PSQI-FSS, BPI-ESS, DS-FSS, DS-BPI and BPI-FSS (p<0,005) prior and post treatment. Patients sleep quality was improved, pain levels decreased and betterment in quality of life was marked (p<0,001). Although significant decrease in fatigue levels was observed (p<0,001) there has been an increase in dyspnea symptoms (p<0,001). Significant improvement was apparent when zoledronic acid was co administered in any treatment in patients with lung cancer. Sleep quality, fatigue and pain parameters also improved, with no positive impact on the symptoms of dyspnea.

DOI10.7150/jca.24785
Alternate JournalJ Cancer
PubMed ID29805698
PubMed Central IDPMC5968760

Contact

Secretariat of the School of Medicine
 

Connect

Schoole of Medicince presence in social networks
Follow Us or Connect with us.